Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 12/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.39 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.39 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.38 |
| ▸ | NNMT | P40261 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743107 | 1.00 | PRMT5 (0.43) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL23120343 | 0.95 | WDR5 (0.44) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL23120342 | 0.95 | WDR5 (0.44) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL23120347 | 0.90 | WDR5 (0.45) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL23120346 | 0.90 | WDR5 (0.45) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL25046812 | 0.88 | PRMT5 (0.46) | PRMT5WDR77METTL3NNMT | |
| SCHEMBL23120190 | 0.88 | WDR5 (0.50) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL23120194 | 0.88 | WDR5 (0.50) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL31713909 | 0.88 | WDR5 (0.50) | PRMT5WDR77WDR5KMT2ARBBP5 | |
| SCHEMBL25046601 | 0.87 | PRMT5 (0.46) | PRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | PRMT5 84/4885WDR77 111/4885WDR5 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.